IL22 and metabolic disease: ILC3s-derived IL-22 can enhance the intestinal mucosal barrier function, reduce endotoxemia and inflammation, ameliorate insulin sensitivity (Wang et al., 2014; Hasnain et al., 2014), and improve the metabolic disorder of polycystic ovary syndrome (Qi et al., 2019).